Literature DB >> 3409231

Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.

R A Mickel1, D J Kessler, J M Taylor, A Lichtenstein.   

Abstract

This study evaluated peripheral blood lymphocyte and lymph node lymphocyte natural killer (NK) cell activity in 22 patients with head and neck squamous cell carcinoma and eight patients undergoing surgery for nonmalignant conditions who served as controls. A novel mixed-model analysis of variance was used to analyze the results because of the inherent difficulties in data interpretation among heterogeneous groups when several concurrent variables impinge upon the results. The peripheral blood lymphocyte NK activity of cancer patients was significantly less than controls. In contrast, lytic activity from uninvolved draining lymph nodes of cancer patients was comparable to the activity of control nodes. However, if the node contained a small focus of metastatic tumor, NK activity was significantly diminished relative to uninvolved nodes from cancer patients or to control nodes. The mixed-model analysis of variance was particularly helpful in confirming this finding. Finally, NK lysis by tumor-infiltrating lymphocytes, purified from grossly metastatic nodes, was severely depressed. These data indicate that a spectrum of NK suppression exists in draining lymph nodes of head and neck squamous cell carcinoma patients, and that the level of activity depends upon the degree of nodal tumor involvement.

Entities:  

Mesh:

Year:  1988        PMID: 3409231

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Lymphotoxin production by regional lymph node lymphocytes in patients with uterine cervical cancer.

Authors:  K Matsunaga; H Mashiba; A Kurano; S Jimi
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

Review 2.  Telltale tumor infiltrating lymphocytes (TIL) in oral, head & neck cancer.

Authors:  Yu Lei; Yuying Xie; Yee Sun Tan; Mark E Prince; Jeffrey S Moyer; Jacques Nör; Gregory T Wolf
Journal:  Oral Oncol       Date:  2016-08-21       Impact factor: 5.337

Review 3.  Biologic markers, cellular differentiation, and metastatic head and neck cancer.

Authors:  S P Schantz
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

4.  Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer.

Authors:  Dejan Baskic; Lazar Vujanovic; Nebojsa Arsenijevic; Theresa L Whiteside; Eugene N Myers; Nikola L Vujanovic
Journal:  Head Neck       Date:  2012-04-05       Impact factor: 3.147

Review 5.  Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.

Authors:  Andre Cassell; Jennifer R Grandis
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

6.  Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs.

Authors:  Kawaljit Kaur; Paytsar Topchyan; Anna Karolina Kozlowska; Nick Ohanian; Jessica Chiang; Phyu Ou Maung; So-Hyun Park; Meng-Wei Ko; Changge Fang; Ichiro Nishimura; Anahid Jewett
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110

7.  Responses of killer cells in head and neck cancer patients.

Authors:  S Fujieda; H Saito; T Hoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

8.  A multicellular tumor spheroid model of cellular immunity against head and neck cancer.

Authors:  P G Sacks; D L Taylor; T Racz; T Vasey; V Oke; S P Schantz
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 9.  Interferons and other cytokines in head and neck cancer.

Authors:  V K Hamasaki; E E Vokes
Journal:  Med Oncol       Date:  1995-03       Impact factor: 3.064

10.  A phase II study of interleukin-2 and interferon-alpha in head and neck cancer.

Authors:  S P Schantz; I Dimery; S M Lippman; G L Clayman; C Pellegrino; R Morice
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.